Search Results
Jan 09, 2026, 02:31 ET No serious adverse events to date in ongoing phase 1/2a clinical study of SYN321
UPPSALA, Sweden, Jan. 9, 2026 /PRNewswire/ -- Synartro is advancing the candidate drug SYN321, a novel intra-articular treatment for knee osteoarthritis, through a phase 1/2a clinical study focused on safety, tolerability, PK, and early efficacy
More news about: Synartro AB
Jan 09, 2026, 02:29 ET No serious adverse events to date in ongoing phase 1/2a clinical study of SYN321
UPPSALA, Sweden, Jan. 9, 2026 /PRNewswire/ -- Synartro is advancing the candidate drug SYN321, a novel intra-articular treatment for knee osteoarthritis, through a phase 1/2a clinical study focused on safety, tolerability, PK, and early efficacy
More news about: Synartro AB
Nov 24, 2025, 09:48 ET NetFoundry Secures Cisco Investments as Strategic Investor in Series A Round
/PRNewswire/ -- NetFoundry today announced that Cisco Investments has joined its Series A funding round as a strategic investor. The Series A, led by SYN Ventures, and first announced earlier this year, now totals over $15 million with the addition of Cisco Investments. NetFoundry's Identity-First Overlays™
More news about: NetFoundry
Nov 24, 2025, 09:00 ET SquareX announces Wipro Ventures as Strategic Partner for Browser Detection and Response, Turning Any Browser into Enterprise-Grade Secure Browser with a Simple Extension
(BDR), announced its strategic partnership with Wipro Ventures, Wipro Limited's investment arm. The investment is part of the company's Series A led by SYN Ventures and Peak XV, which was announced in April this year. This investment marks the tech giant's strategic entry into the fast-growing browser security
More news about: SquareX
Nov 17, 2025, 05:15 ET A SGX Derivatives abre novos caminhos com futuros perpétuos de criptomoedas de nível institucional
bolsa, a SGX permitirá que as instituições negociem e ganhem exposição ao Bitcoin e Ethereum com confiança e escala. Michael Syn, presidente do SGX Group, disse: "Os ativos digitais entraram no portfólio dos investidores institucionais. Demos o próximo passo lógico e deliberado
More news about: Singapore Exchange (SGX)
Nov 17, 2025, 05:12 ET SGX Derivatives slaat een nieuwe weg in met eeuwigdurende cryptofutures van institutioneel niveau
stellen om met vertrouwen en op grote schaal te verhandelen en blootstelling aan Bitcoin en Ethereum te verkrijgen. Michael Syn, voorzitter van SGX Group, verklaart: "Digitale activa hebben hun weg gevonden naar de portefeuille van institutionele beleggers. We hebben de volgende
More news about: Singapore Exchange (SGX)
Nov 17, 2025, 05:10 ET SGX Derivatives percorre nuove strade con i futures perpetui sulle criptovalute di livello istituzionale
consentirà alle istituzioni di negoziare e acquisire esposizione a Bitcoin ed Ethereum con sicurezza e scalabilità. Michael Syn, Presidente di SGX Group, ha affermato: "Gli asset digitali hanno fatto il loro ingresso nel portafoglio degli investitori istituzionali. Abbiamo compiuto
More news about: Singapore Exchange (SGX)
Nov 17, 2025, 05:06 ET SGX Derivatives abre nuevos caminos con futuros perpetuos de criptomonedas de grado institucional
bolsa, SGX permitirá a las instituciones operar y obtener exposición a Bitcoin y Ethereum con confianza y a gran escala. Michael Syn, presidente, SGX Group, comentó, "Los activos digitales se han incorporado a las carteras de los inversores institucionales. Hemos dado el siguiente
More news about: Singapore Exchange (SGX)
Nov 17, 2025, 05:02 ET SGX Derivatives beschreitet mit institutionellen Krypto-Perpetual-Futures neue Wege
institutionellen Anlegern, Bitcoin und Ethereum mit Vertrauen und in großem Umfang zu handeln und sich darin zu engagieren. Michael Syn, Präsident der SGX Group, sagte: „Digitale Vermögenswerte haben Einzug in die Portfolios institutioneller Anleger gehalten. Wir haben den nächsten logischen
More news about: Singapore Exchange (SGX)
Nov 17, 2025, 05:00 ET SGX Derivatives innove avec des contrats à terme perpétuels de qualité institutionnelle, sur crypto-monnaies
permettra aux institutions de négocier et de s'exposer au Bitcoin et à l'Ethereum en toute confiance et à grande échelle. Michael Syn, président du groupe SGX, a déclaré : « Les actifs digitaux ont fait leur entrée dans le portefeuille des investisseurs institutionnels. Nous avons franchi
More news about: Singapore Exchange (SGX)
Nov 17, 2025, 04:58 ET SGX Derivatives abre nuevos caminos con futuros perpetuos sobre criptomonedas de grado institucional
bolsa, SGX permitirá a las instituciones operar y obtener exposición a Bitcoin y Ethereum con confianza y a gran escala. Michael Syn, presidente de SGX Group, afirmó: "Los activos digitales se han abierto paso en las carteras de los inversores institucionales. Hemos dado el siguiente
More news about: Singapore Exchange (SGX)
Nov 17, 2025, 04:55 ET SGX Derivatives breaks new ground with institutional-grade crypto perpetual futures
on-exchange, SGX will enable institutions to trade and gain exposure to Bitcoin and Ethereum with confidence and scale. Michael Syn, President, SGX Group, said, "Digital assets have made their way into institutional investors' portfolio. We have taken the next logical and deliberate
More news about: Singapore Exchange (SGX)
Nov 17, 2025, 04:36 ET SGX Derivatives Hadirkan Terobosan dengan Meluncurkan Instrumen "Crypto Perpetual Futures" Berstandar Investor Institusi
institusi untuk memperdagangkan dan memperoleh akses Bitcoin dan Ethereum dengan mekanisme yang lebih aman dalam skala besar. Michael Syn, President, SGX Group, berkata, "Aset digital kini telah menjadi bagian dari portofolio investor institusi. Untuk itu, kami mengambil langkah
More news about: Singapore Exchange (SGX)
Nov 17, 2025, 04:36 ET SGX Derivatives breaks new ground with institutional-grade crypto perpetual futures
institutions to trade and gain exposure to Bitcoin and Ethereum with confidence and scale. Michael Syn, President, SGX Group, said, "Digital assets have made their way into institutional investors' portfolio. We have taken the next logical and deliberate
More news about: Singapore Exchange (SGX)
Nov 11, 2025, 08:07 ET CND Life Sciences' Syn-One® Biomarker Services Used for Novel Parkinson's Disease Endpoint in Phase 2 Drug Trial
preliminary data generated using our Syn-One Biomarker Services in ABLi's 201 Trial for risvodetinib," said Christopher Gibbons, MD, chief scientific officer of CND. "While additional work needs to be done in future trials, these results support the potential role Syn-One can play in helping to quantify
More news about: CND Life Sciences
Nov 11, 2025, 04:24 ET atNorth Announces Management Team Expansion as Part of Next Level Growth Strategy
development, sustainability, and sales to ensure clarity and scalability in delivery. Prior to joining atNorth, Bára held senior program leadership roles at Syn and Marel, where she led complex digital transformation initiatives and drove cross-functional alignment between technology, operations, and business
More news about: atNorth
Nov 11, 2025, 04:21 ET atNorth Announces Management Team Expansion as Part of Next Level Growth Strategy
development, sustainability, and sales to ensure clarity and scalability in delivery. Prior to joining atNorth, Bára held senior program leadership roles at Syn and Marel, where she led complex digital transformation initiatives and drove cross-functional alignment between technology, operations, and business
More news about: atNorth
Nov 06, 2025, 08:07 ET Using Skin Biopsy Technology, CND Life Sciences Performs the 50,000th Syn-One Test® for Patients
Syn-One Test. The Syn-One Test is a laboratory developed test (LDT) designed to aid clinicians in the diagnosis of synucleinopathies like Parkinson's disease (PD),
More news about: CND Life Sciences
Nov 05, 2025, 09:00 ET SquareX Named SINET16 Innovator for Browser Detection and Response
Awards in service of our mission: to advance innovation to defeat global cybersecurity threats," said Robert Rodriguez, Chairman, SINET, Venture Partner, SYN Ventures. "Innovation begins with increased awareness of new and emerging technologies that will better society. Through the SINET16 application process,
More news about: SquareX
Oct 28, 2025, 09:00 ET Conifers Announces Strategic Investment from Washington Harbour Partners to Scale CognitiveSOC for Government Missions
helps security teams investigate complex, multi-tier incidents with speed, accuracy, and trust. Led by seasoned cybersecurity leaders and backed by SYN Ventures, PICUS Capital, and Washington Harbour Partners, the company brings deep industry knowledge and innovation to an increasingly AI-driven threat
More news about: Conifers
Oct 27, 2025, 08:00 ET KnowBe4 Student Edition Achieves Milestone of One Million Students Trained
beyond just training students; it contributes toward building a true security culture at high school and university campuses across the world," Ben Syn, director, university and career education, KnowBe4. "Our unwavering commitment to education extends beyond our industry-leading platform, because we
More news about: KnowBe4 Inc.
Oct 22, 2025, 08:07 ET CND Life Sciences Announces NIH Grant to Study the Risk of Parkinson's Disease in Patients with Essential Tremor
Syn-One Test® will be studied as a predictive tool to help assess which patients may be at risk for developing PD. Outcomes from the "Syn-T Study" could have major implications for the treatment and management of
More news about: CND Life Sciences
Oct 12, 2025, 22:01 ET Vantage imponerar som Titanium-sponsor på Money Expo Chile 2025
Martínez, Business Development Team Lead, medverkade i en paneldiskussion på temat "AI Integration Strategies in Trading Operations" där han gav sin syn på hur ny teknik, i synnerhet artificiell intelligens, förändrar börshandeln.
More news about: Vantage
Oct 07, 2025, 13:22 ET CND Life Sciences is Granted FDA Breakthrough Device Designation for Its Skin Biopsy-Based Syn-One Test®
large health systems. Through a routine office-based procedure, Syn-One uses three small skin biopsy samples collected from three specific anatomical locations on each patient to identify the abnormal, phosphorylated alpha-synuclein (P-SYN) protein in cutaneous nerves, while also measuring intraepidermal
More news about: CND Life Sciences
Oct 07, 2025, 11:51 ET WaveBreak Presents Human Brain Tissue Data Demonstrating Binding and Efficacy of Small Molecule WTX-607 Against Alpha-Synuclein Aggregates for Parkinson's Disease and Lewy Body Dementia
brain tissue of Parkinson's and Lewy body dementia patients has unlocked the capability to assess on-target engagement and efficacy for inhibiting α-syn aggregation as well as α-synuclein kinetics, which has predictive potential for progression to cognitive impairment." These human
More news about: WaveBreak